Category Archives: Corporate

Latest From Corporate

BIO Welcomes Seven New Board Members


BIO elected seven new members to its Board of Directors, voted upon at this year’s Board Meetings, held this week in New York City. The following individuals were elected to the Health Section Governing Board: Christopher Boerner, President and Head of the U.S. Commercial Business, BMS Mark Alles, President and Chief Operating Officer, Celgene Gary Zieziula, President and Managing Director, EMD Serono Elizabeth Lewis, Chief Counsel and Chief Compliance Officer, Takeda Pharmaceuticals Jean-Christophe Tellier, Chief Read More >

Corporate  |  Leave a comment  |  Email This Post
Tags: , ,

The New Biotechnology Innovation Organization


At BIO, new discoveries in research and development are constantly being made by our members. We take pride in the contributions they have made across a diverse range of biotechnology industries, including: healthcare, agricultural, industrial and environmental. As one of the world’s strongest catalysts for innovation, our role within the biotechnology community requires us to reflect on who we are, what we do and how we can better serve our members in future. Biotechnology scientists Read More >

Jim's Corner  |  Leave a comment  |  Email This Post

Driving Innovation in Cancer: Startup Challenge

The Center for Advancing Innovation (CAI) announces the launch of the Nanotechnology Startup Challenge for Cancer (NSC2). NSC2 is an open innovation competition designed to bring promising cancer nanotechnology inventions to market.

Corporate  |  Leave a comment  |  Email This Post

Wall Street Journal: Patients Deserve Better


In case you missed it, The Wall Street Journal published my Letter to the Editor this morning.  I make the point that the problem isn’t innovative new treatments from America’s biopharma industry but rather the complex web of health-insurance schemes patients must navigate to access needed medicines. Here is the text of the letter: “Innovative treatments and cures have radically transformed how we treat disease—saving and improving lives and providing tremendous benefits to patients and Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , ,

Ezekiel Emanuel’s Flawed Solution

Jim Greenwood

In a New York Times op-ed today, Dr. Ezekiel Emanuel proposes “The Solution to Drug Prices.” The piece is problematic in many respects, but we agree with one of his primary contentions: in discussions about drug prices, value is the real issue. This point was nicely made in a recent Times piece, where it quoted Crystal Bedford, whose five year old daughter, Marley, suffers from a rare genetic disease, Rhizomelic Chondrodysplasia Punctata (RCPD). A treatment Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,